| James Patrick Ford, | |
|
4315 Diplomacy Dr, Anchorage, AK 99508-5926 | |
| (907) 729-1400 | |
| Not Available |
| Full Name | James Patrick Ford |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 13 Years |
| Location | 4315 Diplomacy Dr, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144511304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 01075691A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alaska Native Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Native Tribal Health Consortium | 6709780265 | 457 |
| Yukon-kuskokwim Health Corporation | 5193718765 | 77 |
News Archive
Patients hospitalized for either asthma or chronic obstructive pulmonary disease have a higher risk of being readmitted for a hospital stay within 30 days of release if they also suffer from chronic rhinitis, according to a trio of researchers at the University of Cincinnati.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
Correcting the timing of heart contractions through cardiac resynchronization therapy can be a lifesaver for people with advanced heart failure. But the procedure, as it is done today, fails in about 15 percent of patients.
An interdisciplinary team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg led by Prof. Aldo R. Boccaccini from the Chair of Materials Science (biomaterials) and Prof. Dr. Ralf Dittrich from the Department of Obstetrics and Gynaecology at Universitätsklinikum Erlangen have taken an important step towards developing artificial ovaries for patients suffering from cancer.
Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
› Verified 8 days ago
| Entity Name | Southeast Alaska Regional Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376758037 PECOS PAC ID: 1456265362 Enrollment ID: O20031114000631 |
News Archive
Patients hospitalized for either asthma or chronic obstructive pulmonary disease have a higher risk of being readmitted for a hospital stay within 30 days of release if they also suffer from chronic rhinitis, according to a trio of researchers at the University of Cincinnati.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
Correcting the timing of heart contractions through cardiac resynchronization therapy can be a lifesaver for people with advanced heart failure. But the procedure, as it is done today, fails in about 15 percent of patients.
An interdisciplinary team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg led by Prof. Aldo R. Boccaccini from the Chair of Materials Science (biomaterials) and Prof. Dr. Ralf Dittrich from the Department of Obstetrics and Gynaecology at Universitätsklinikum Erlangen have taken an important step towards developing artificial ovaries for patients suffering from cancer.
Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
› Verified 8 days ago
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
Patients hospitalized for either asthma or chronic obstructive pulmonary disease have a higher risk of being readmitted for a hospital stay within 30 days of release if they also suffer from chronic rhinitis, according to a trio of researchers at the University of Cincinnati.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
Correcting the timing of heart contractions through cardiac resynchronization therapy can be a lifesaver for people with advanced heart failure. But the procedure, as it is done today, fails in about 15 percent of patients.
An interdisciplinary team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg led by Prof. Aldo R. Boccaccini from the Chair of Materials Science (biomaterials) and Prof. Dr. Ralf Dittrich from the Department of Obstetrics and Gynaecology at Universitätsklinikum Erlangen have taken an important step towards developing artificial ovaries for patients suffering from cancer.
Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
› Verified 8 days ago
| Entity Name | Yukon-kuskokwim Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447477815 PECOS PAC ID: 5193718765 Enrollment ID: O20040407001515 |
News Archive
Patients hospitalized for either asthma or chronic obstructive pulmonary disease have a higher risk of being readmitted for a hospital stay within 30 days of release if they also suffer from chronic rhinitis, according to a trio of researchers at the University of Cincinnati.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
Correcting the timing of heart contractions through cardiac resynchronization therapy can be a lifesaver for people with advanced heart failure. But the procedure, as it is done today, fails in about 15 percent of patients.
An interdisciplinary team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg led by Prof. Aldo R. Boccaccini from the Chair of Materials Science (biomaterials) and Prof. Dr. Ralf Dittrich from the Department of Obstetrics and Gynaecology at Universitätsklinikum Erlangen have taken an important step towards developing artificial ovaries for patients suffering from cancer.
Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Patrick Ford, 2809 Discovery Bay Dr, Anchorage, AK 99515-2748 Ph: () - | James Patrick Ford, 4315 Diplomacy Dr, Anchorage, AK 99508-5926 Ph: (907) 729-1400 |
News Archive
Patients hospitalized for either asthma or chronic obstructive pulmonary disease have a higher risk of being readmitted for a hospital stay within 30 days of release if they also suffer from chronic rhinitis, according to a trio of researchers at the University of Cincinnati.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
Correcting the timing of heart contractions through cardiac resynchronization therapy can be a lifesaver for people with advanced heart failure. But the procedure, as it is done today, fails in about 15 percent of patients.
An interdisciplinary team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg led by Prof. Aldo R. Boccaccini from the Chair of Materials Science (biomaterials) and Prof. Dr. Ralf Dittrich from the Department of Obstetrics and Gynaecology at Universitätsklinikum Erlangen have taken an important step towards developing artificial ovaries for patients suffering from cancer.
Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
› Verified 8 days ago
David Zumbro, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3500 Latouche St, Suite 250, Anchorage, AK 99508 Phone: 907-561-1530 | |
Dr. Richard Kevin Winkle, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3500 Latouche St Ste 280, Anchorage, AK 99508 Phone: 907-561-1917 | |
Julia D Shatten, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 542 W 2nd Ave, Anchorage, AK 99501 Phone: 907-276-1617 | |
Dr. James Richard Townley Iii, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-1162 | |
Elaine Rose Mcelhinny, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3801 University Lake Dr Fl 2, Anchorage, AK 99508 Phone: 646-506-3297 | |
Carl Eli Rosen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 542 W 2nd Ave, Anchorage, AK 99501 Phone: 907-276-1617 Fax: 907-264-2687 |